MedTrace Logo

Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms

NCT00332644 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1504

Last updated 2011-11-30

Study results available
· View outcomes & findings →

Summary

The proposed work will advance the understanding and effectiveness of tobacco dependence treatment and result in more smokers quitting successfully.

Conditions

  • Nicotine Dependence

Interventions

DRUG

nicotine patch

used according to FDA package label

DRUG

nicotine lozenge

used according to FDA-approved package directions

DRUG

nicotine patch + nicotine lozenge

dosage of both according to FDA-approved dosing schedule

DRUG

bupropion

dosage according to FDA-approved instructions

DRUG

bupropion + lozenge

dosage according to FDA approved standard instructions

DRUG

placebo

dosage same as active drug conditions

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Timothy B. Baker, PhD · University of Wisconsin, Madison

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00332644 on ClinicalTrials.gov